ArticleJournal of immunology (Baltimore, Md. : 1950)2009
TLR3-stimulated dendritic cells up-regulate B7-H1 expression and influence the magnitude of CD8 T cell responses to tumor vaccination.
Article in Journal of immunology (Baltimore, Md. : 1950), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
78 citing papers in PubMed, 118 citations in OpenAlex.
- Insight of immune checkpoint blockades in melanoma: mechanism and clinical translation.Molecular cancer · 2026Review
- Beyond the tumor microenvironment: a hierarchical immune-circuit model of immune checkpoint blockade resistance.Frontiers in oncology · 2026Review
- Proteomics analysis and immune profiling reveal regulators of PD-L1 in oesophageal squamous cell carcinoma.British journal of cancer · 2025Article
- Lefitolimod in Combination with Ipilimumab in Patients with Advanced Solid Tumors: A Phase I Trial.Journal of immunotherapy and precision oncology · 2025Article
- Development of an immunogenic cell death-related lncRNAs signature for prognostic risk assessment in gastric cancer.Translational cancer research · 2024Article
- Bidirectional crosstalk between therapeutic cancer vaccines and the tumor microenvironment: Beyond tumor antigens.Fundamental research · 2023Review
- Rescue of dendritic cells from glycolysis inhibition improves cancer immunotherapy in mice.Nature communications · 2023Article
- Role of regulation of PD-1 and PD-L1 expression in sepsis.Frontiers in immunology · 2023Review
- A Novel Humanized PD-1/PD-L1 Mouse Model Permits Direct Comparison of Antitumor Immunity Generated by Food and Drug Administration-Approved PD-1 and PD-L1 Inhibitors.ImmunoHorizons · 2023Article
- Programmed Cell Death-Ligand 1 in Head and Neck Squamous Cell Carcinoma: Molecular Insights, Preclinical and Clinical Data, and Therapies.International journal of molecular sciences · 2022Review
- Article
- Enhancement of protective efficacy of innate immunostimulant based formulations against yolk sac infection in young chicks.Poultry science · 2022Article
- Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics.Nature reviews. Clinical oncology · 2022Review
- Antitumor Peptide-Based Vaccine in the Limelight.Vaccines · 2022Review
- Understanding the functional inflammatory factors involved in therapeutic response to immune checkpoint inhibitors for pan-cancer.Frontiers in pharmacology · 2022Review
- Autophagy controls programmed death-ligand 1 expression on cancer cells (Review).Biomedical reports · 2021Review
- Perspectives on immune checkpoint ligands: expression, regulation, and clinical implications.BMB reports · 2021Review
- Therapeutic vaccination targeting CD40 and TLR3 controls melanoma growth through existing intratumoral CD8 T cells without new T cell infiltration.Cancer immunology, immunotherapy : CII · 2021Article
- An analysis of the immunological tumor microenvironment of primary tumors and regional lymph nodes in squamous cell lung cancer.Translational lung cancer research · 2021Article
- A TLR4 agonist improves immune checkpoint blockade treatment by increasing the ratio of effector to regulatory cells within the tumor microenvironment.Scientific reports · 2021Article
18 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Agonists of TLR have been explored as vaccine adjuvants for tumor immunotherapy. However, their immunological consequences are not fully understood. Although TLR signaling increases the functional potential of dendritic cells (DCs) for priming T cells, coinduction of potentially negative immunoregulatory capacities may impair effector T cell generation. We examined the expression and function of B7 family costimulatory molecules on DCs after activation with the TLR3 agonist, polyinosinic:polycytidylic acid. We demonstrated that polyinosinic:polycytidylic acid consistently up-regulated both B7-2 and B7-H1 molecules on resident, migratory DCs from spleen and lymph nodes. Depletion or blockade of B7-H1 on activated DCs increased the magnitude of effector CD8 T cell expansion. DC-based or protein-based tumor vaccines, in combination with B7-H1 blockade, induced strong effector CD8 T cell responses, resulting in protective immunity against newly established tumors. Our studies suggest that TLR3 signaling has the potential to up-regulate both positive and negative coregulatory molecules on APCs. Selective blockade of negative regulatory molecules in combination with TLR3 agonist may be an effective strategy for increasing the efficacy of tumor vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.